Roy H Perlis

List of Publications by Year
in descending order

241 papers	20,448 citations	17429 63 h-index	13365 130 g-index
261 all docs	261 docs citations	261 times ranked	21437 citing authors

#	Article	IF	Citations
1	Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders. Biological Psychiatry, 2022, 91, 102-117.	0.7	61
2	The value of intrapartum factors in predicting maternal morbidity. American Journal of Obstetrics & Gynecology MFM, 2022, 4, 100485.	1.3	5
3	Trends in Female Authorship in High Impact Surgical Journals Between 2008 and 2018. Annals of Surgery, 2022, 275, e115-e123.	2.1	20
4	Longitudinal validation of an electronic health record delirium prediction model applied at admission in COVID-19 patients. General Hospital Psychiatry, 2022, 74, 9-17.	1.2	7
5	Association of Major Depressive Symptoms With Endorsement of COVID-19 Vaccine Misinformation Among US Adults. JAMA Network Open, 2022, 5, e2145697.	2.8	23
6	Prenatal origins of suicide mortality: A prospective cohort study in the United States. Translational Psychiatry, 2022, 12, 14.	2.4	1
7	Patient-Derived InÂVitro Models of Microglial Function and Synaptic Engulfment in Schizophrenia. Biological Psychiatry, 2022, 92, 470-479.	0.7	20
8	A bidirectional competitive interaction between circHomer1 and Homer1b within the orbitofrontal cortex regulates reversal learning. Cell Reports, 2022, 38, 110282.	2.9	17
9	Estimating longitudinal depressive symptoms from smartphone data in a transdiagnostic cohort. Brain and Behavior, 2022, 12, e02077.	1.0	8
10	Is It Time to Try Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Again?. JAMA Psychiatry, 2022, , .	6.0	3
11	Prevalence of Firearm Ownership Among Individuals With Major Depressive Symptoms. JAMA Network Open, 2022, 5, e223245.	2.8	7
12	COVID-19 in pregnancy: implications for fetal brain development. Trends in Molecular Medicine, 2022, 28, 319-330.	3.5	70
13	Efficiently identifying individuals at high risk for treatment resistance in major depressive disorder using electronic health records. Journal of Affective Disorders, 2022, 306, 254-259.	2.0	7
14	Genetic Association of Attention-Deficit/Hyperactivity Disorder and Major Depression With Suicidal Ideation and Attempts in Children: The Adolescent Brain Cognitive Development Study. Biological Psychiatry, 2022, 92, 236-245.	0.7	17
15	Natural language processing of admission notes to predict severe maternal morbidity during the delivery encounter. American Journal of Obstetrics and Gynecology, 2022, 227, 511.e1-511.e8.	0.7	7
16	Do clinicians follow heuristics in prescribing antidepressants?. Journal of Affective Disorders, 2022, , .	2.0	2
17	Human cerebral spheroids undergo 4-aminopyridine-induced, activity associated changes in cellular composition and microrna expression. Scientific Reports, 2022, 12, .	1.6	2
18	Neurodevelopmental Outcomes at 1 Year in Infants of Mothers Who Tested Positive for SARS-CoV-2 During Pregnancy. JAMA Network Open, 2022, 5, e2215787.	2.8	111

#	Article	IF	Citations
19	Case-control study of neuropsychiatric symptoms in electronic health records following COVID-19 hospitalization in 2 academic health systems. Molecular Psychiatry, 2022, 27, 3898-3903.	4.1	13
20	Mending the Holes in the Suicide Safety Net. JAMA Network Open, 2022, 5, e2225794.	2.8	1
21	N-3 polyunsaturated fatty acids promote astrocyte differentiation and neurotrophin production independent of cAMP in patient-derived neural stem cells. Molecular Psychiatry, 2021, 26, 4605-4615.	4.1	29
22	Advances toward precision medicine for bipolar disorder: mechanisms & molecules. Molecular Psychiatry, 2021, 26, 168-185.	4.1	36
23	Distribution of agitation and related symptoms among hospitalized patients using a scalable natural language processing method. General Hospital Psychiatry, 2021, 68, 46-51.	1.2	8
24	Predicting change in diagnosis from major depression to bipolar disorder after antidepressant initiation. Neuropsychopharmacology, 2021, 46, 455-461.	2.8	17
25	Authorship inequality: a bibliometric study of the concentration of authorship among a diminishing number of individuals in high-impact medical journals, 2008â€"2019. BMJ Open, 2021, 11, e046002.	0.8	8
26	Adaptor Protein ShcD/<i>SHC4</i> Interacts with Tie2 Receptor to Synergistically Promote Glioma Cell Invasion. Molecular Cancer Research, 2021, 19, 757-770.	1.5	6
27	Hard for humans, hard for machines: predicting readmission after psychiatric hospitalization using narrative notes. Translational Psychiatry, 2021, 11, 32.	2.4	11
28	Frequency and profile of objective cognitive deficits in hospitalized patients recovering from COVID-19. Neuropsychopharmacology, 2021, 46, 2235-2240.	2.8	157
29	How machine-learning recommendations influence clinician treatment selections: the example of antidepressant selection. Translational Psychiatry, 2021, 11, 108.	2.4	73
30	Association of Acute Symptoms of COVID-19 and Symptoms of Depression in Adults. JAMA Network Open, 2021, 4, e213223.	2.8	43
31	The utility of electronic health record data for identifying postpartum hemorrhage. American Journal of Obstetrics & Gynecology MFM, 2021, 3, 100305.	1.3	4
32	Development and External Validation of a Delirium Prediction Model for Hospitalized Patients With Coronavirus Disease 2019. Journal of the Academy of Consultation-Liaison Psychiatry, 2021, 62, 298-308.	0.2	14
33	Umbilical cord blood-derived microglia-like cells to model COVID-19 exposure. Translational Psychiatry, 2021, 11, 179.	2.4	11
34	Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nature Genetics, 2021, 53, 817-829.	9.4	629
35	The role of race, religion, and partisanship in misperceptions about COVID-19. Group Processes and Intergroup Relations, 2021, 24, 638-657.	2.4	38
36	The association between genetically determined ABO blood types and major depressive disorder. Psychiatry Research, 2021, 299, 113837.	1.7	4

#	Article	IF	Citations
37	Derivation and external validation of risk stratification models for severe maternal morbidity using prenatal encounter diagnosis codes. Journal of Perinatology, 2021, 41, 2590-2596.	0.9	5
38	Phenotypic signatures in clinical data enable systematic identification of patients for genetic testing. Nature Medicine, 2021, 27, 1097-1104.	15.2	21
39	Factors Associated With Self-reported Symptoms of Depression Among Adults With and Without a Previous COVID-19 Diagnosis. JAMA Network Open, 2021, 4, e2116612.	2.8	12
40	Mood Disorders and Outcomes of COVID-19 Hospitalizations. American Journal of Psychiatry, 2021, 178, 541-547.	4.0	18
41	Assessment of the Performance Consistency of an Adverse Outcome Prediction Tool for Patients Hospitalized With COVID-19. JAMA Network Open, 2021, 4, e2118413.	2.8	0
42	Stratified delirium risk using prescription medication data in a state-wide cohort. General Hospital Psychiatry, 2021, 71, 114-120.	1.2	4
43	Mapping of Transdiagnostic Neuropsychiatric Phenotypes Across Patients in Two General Hospitals. Journal of the Academy of Consultation-Liaison Psychiatry, 2021, 62, 430-439.	0.2	3
44	Genderâ€specificity of resilience in major depressive disorder. Depression and Anxiety, 2021, 38, 1026-1033.	2.0	9
45	The use of a validated obstetrical risk score for maternal morbidity to predict postpartum hemorrhage for women in labor. American Journal of Obstetrics and Gynecology, 2021, 225, 199-200.	0.7	5
46	Transcriptome-based polygenic score links depression-related corticolimbic gene expression changes to sex-specific brain morphology and depression risk. Neuropsychopharmacology, 2021, 46, 2304-2311.	2.8	5
47	Preferential Mixture-of-Experts: Interpretable Models that Rely on Human Expertise As Much As Possible. AMIA Summits on Translational Science Proceedings, 2021, 2021, 525-534.	0.4	0
48	Association Between Social Media Use and Self-reported Symptoms of Depression in US Adults. JAMA Network Open, 2021, 4, e2136113.	2.8	17
49	Characterizing DSM-5 and ICD-11 personality disorder features in psychiatric inpatients at scale using electronic health records. Psychological Medicine, 2020, 50, 2221-2229.	2.7	15
50	What do patients learn about psychotropic medications on the web? A natural language processing study. Journal of Affective Disorders, 2020, 260, 366-371.	2.0	9
51	Translating Discoveries in Attention-Deficit/Hyperactivity Disorder Genomics to an Outpatient Child and Adolescent Psychiatric Cohort. Journal of the American Academy of Child and Adolescent Psychiatry, 2020, 59, 964-977.	0.3	16
52	Deep Learning Benchmarks on L1000 Gene Expression Data. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2020, 17, 1846-1857.	1.9	9
53	Stratifying risk for dementia onset using largeâ€scale electronic health record data: A retrospective cohort study. Alzheimer's and Dementia, 2020, 16, 531-540.	0.4	28
54	Association between DSM-5 and ICD-11 personality dimensional traits in a general medical cohort and readmission and mortality. General Hospital Psychiatry, 2020, 64, 63-67.	1.2	8

#	Article	IF	Citations
55	Further evidence of low adherence to stimulant treatment in adult ADHD: an electronic medical record study examining timely renewal of a stimulant prescription. Psychopharmacology, 2020, 237, 2835-2843.	1.5	15
56	In vivo human brain expression of histone deacetylases in bipolar disorder. Translational Psychiatry, 2020, 10, 224.	2.4	17
57	Differences among Research Domain Criteria score trajectories by Diagnostic and Statistical Manual categorical diagnosis during inpatient hospitalization. PLoS ONE, 2020, 15, e0237698.	1.1	8
58	Essential Work: Psychiatric Clinical Investigation in the Midst of a Pandemic. American Journal of Psychiatry, 2020, 177, 1117-1118.	4.0	1
59	Laboratory Findings Associated With Severe Illness and Mortality Among Hospitalized Individuals With Coronavirus Disease 2019 in Eastern Massachusetts. JAMA Network Open, 2020, 3, e2023934.	2.8	51
60	Randomized, controlled, participantâ€•and raterâ€•blind trial of pharmacogenomic testâ€•guided treatment versus treatment as usual for major depressive disorder. Depression and Anxiety, 2020, 37, 834-841.	2.0	31
61	Assessment of a Prediction Model for Antidepressant Treatment Stability Using Supervised Topic Models. JAMA Network Open, 2020, 3, e205308.	2.8	15
62	Electronic Health Record Documentation of Psychiatric Assessments in Massachusetts Emergency Department and Outpatient Settings During the Coronavirus Disease 2019 (COVID-19) Pandemic. JAMA Network Open, 2020, 3, e2011346.	2.8	18
63	Transcriptomic Landscape and Functional Characterization of Induced Pluripotent Stem Cellâ€"Derived Cerebral Organoids in Schizophrenia. JAMA Psychiatry, 2020, 77, 745.	6.0	102
64	Exercising Heart and Head in Managing Coronavirus Disease 2019 in Wuhan. JAMA Network Open, 2020, 3, e204006.	2.8	44
65	Minimal phenotyping yields genome-wide association signals of low specificity for major depression. Nature Genetics, 2020, 52, 437-447.	9.4	207
66	Predicting treatment dropout after antidepressant initiation. Translational Psychiatry, 2020, 10, 60.	2.4	22
67	A psychiatric disease-related circular RNA controls synaptic gene expression and cognition. Molecular Psychiatry, 2020, 25, 2712-2727.	4.1	100
68	A Summary of Recent Updates on the Genetic Determinants of Depression. , 2020, , 1-27.		1
69	Integrating questionnaire measures for transdiagnostic psychiatric phenotyping using word2vec. PLoS ONE, 2020, 15, e0230663.	1.1	3
70	Health Care Consumer Shopping Behaviors and Sentiment: Qualitative Study. Journal of Participatory Medicine, 2020, 12, e13924.	0.7	5
71	Integrating questionnaire measures for transdiagnostic psychiatric phenotyping using word2vec. , 2020, 15, e0230663.		0
72	Integrating questionnaire measures for transdiagnostic psychiatric phenotyping using word2vec. , 2020, 15, e0230663.		0

#	Article	IF	Citations
73	Integrating questionnaire measures for transdiagnostic psychiatric phenotyping using word2vec. , 2020, 15, e0230663.		0
74	Integrating questionnaire measures for transdiagnostic psychiatric phenotyping using word2vec. , 2020, 15, e0230663.		0
75	Attention-Deficit/Hyperactivity Disorder, Hypomania, and Bipolar Disorder in Youth. JAMA Psychiatry, 2019, 76, 1119.	6.0	0
76	Evidence of Low Adherence to Stimulant Medication Among Children and Youths With ADHD: An Electronic Health Records Study. Psychiatric Services, 2019, 70, 874-880.	1.1	34
77	Prevalence of Financial Considerations Documented in Primary Care Encounters as Identified by Natural Language Processing Methods. JAMA Network Open, 2019, 2, e1910399.	2.8	6
78	Evaluating Machine Learning Articles. JAMA - Journal of the American Medical Association, 2019, 322, 1777.	3.8	28
79	Aberrant mitochondrial function in patient-derived neural cells from CDKL5 deficiency disorder and Rett syndrome. Human Molecular Genetics, 2019, 28, 3625-3636.	1.4	19
80	Can electronic health records revive central nervous system clinical trials?. Molecular Psychiatry, 2019, 24, 1096-1098.	4.1	9
81	Dysregulated protocadherin-pathway activity as an intrinsic defect in induced pluripotent stem cellâ€"derived cortical interneurons from subjects with schizophrenia. Nature Neuroscience, 2019, 22, 229-242.	7.1	84
82	Peripheral and central levels of kynurenic acid in bipolar disorder subjects and healthy controls. Translational Psychiatry, 2019, 9, 37.	2.4	51
83	Using phenome-wide association to investigate the function of a schizophrenia risk locus at SLC39A8. Translational Psychiatry, 2019, 9, 45.	2.4	18
84	Research Domain Criteria scores estimated through natural language processing are associated with risk for suicide and accidental death. Depression and Anxiety, 2019, 36, 392-399.	2.0	23
85	Activation of WNT and CREB signaling pathways in human neuronal cells in response to the Omega-3 fatty acid docosahexaenoic acid (DHA). Molecular and Cellular Neurosciences, 2019, 99, 103386.	1.0	19
86	Trends in Proportion of Women as Authors of Medical Journal Articles, 2008-2018. JAMA Internal Medicine, 2019, 179, 1285.	2.6	74
87	Association between child psychiatric emergency room outcomes and dimensions of psychopathology. General Hospital Psychiatry, 2019, 59, 1-6.	1.2	12
88	Genome-wide association study identifies 30 loci associated with bipolar disorder. Nature Genetics, 2019, 51, 793-803.	9.4	1,191
89	Psychosis with Methylphenidate or Amphetamine in Patients with ADHD. New England Journal of Medicine, 2019, 380, 1128-1138.	13.9	114
90	Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia. JAMA Psychiatry, 2019, 76, 691.	6.0	18

#	Article	IF	Citations
91	Gender Trends in Authorship in Psychiatry Journals From 2008 to 2018. Biological Psychiatry, 2019, 86, 639-646.	0.7	49
92	Contribution of Rare Copy Number Variants to Bipolar Disorder Risk Is Limited to Schizoaffective Cases. Biological Psychiatry, 2019, 86, 110-119.	0.7	45
93	Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. Nature Neuroscience, 2019, 22, 374-385.	7.1	511
94	Genome-wide Association Study of Dimensional Psychopathology Using Electronic Health Records. Biological Psychiatry, 2018, 83, 1005-1011.	0.7	23
95	High Throughput Phenotyping for Dimensional Psychopathology in Electronic Health Records. Biological Psychiatry, 2018, 83, 997-1004.	0.7	56
96	Genetic validation of bipolar disorder identified by automated phenotyping using electronic health records. Translational Psychiatry, 2018, 8, 86.	2.4	24
97	Anxiety About Antidepressants. American Journal of Psychiatry, 2018, 175, 500-501.	4.0	5
98	Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma. Scientific Reports, 2018, 8, 5437.	1.6	14
99	Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nature Genetics, 2018, 50, 668-681.	9.4	2,224
100	Genome-wide association identifies a novel locus for delirium risk. Neurobiology of Aging, 2018, 68, 160.e9-160.e14.	1.5	14
101	Assessment of Time-Series Machine Learning Methods for Forecasting Hospital Discharge Volume. JAMA Network Open, 2018, 1, e184087.	2.8	32
102	Advancing Health and Health Care Using Machine Learning. JAMA Network Open, 2018, 1, e187176.	2.8	4
103	Prevalence and Nature of Financial Considerations Documented in Narrative Clinical Records in Intensive Care Units. JAMA Network Open, 2018, 1, e184178.	2.8	6
104	Temporal Trends and Characteristics of Reportable Health Data Breaches, 2010-2017. JAMA - Journal of the American Medical Association, 2018, 320, 1282.	3.8	36
105	Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies. European Neuropsychopharmacology, 2018, 28, 945-954.	0.3	64
106	Cohort study of the relationship between individual psychotherapy and pregnancy outcomes. Journal of Affective Disorders, 2018, 239, 253-257.	2.0	9
107	Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity-score matched study. Depression and Anxiety, 2018, 35, 946-952.	2.0	29
108	No Association Between Antidepressant Efficacy and rs28365143 in Corticotropin-Releasing Hormone Binding Protein in a Large Meta-Analysis. American Journal of Psychiatry, 2018, 175, 575-576.	4.0	1

#	Article	IF	Citations
109	Impairment in delay discounting in schizophrenia and schizoaffective disorder but not primary mood disorders. NPJ Schizophrenia, 2018, 4, 9.	2.0	25
110	Enhancing Delirium Case Definitions in Electronic Health Records Using Clinical Free Text. Psychosomatics, 2017, 58, 113-120.	2.5	22
111	Improving discrimination in antepartum depression screening using the Edinburgh Postnatal Depression Scale. Journal of Affective Disorders, 2017, 214, 1-7.	2.0	8
112	Characterizing and predicting rates of delirium across general hospital settings. General Hospital Psychiatry, 2017, 46, 1-6.	1.2	25
113	Validation of a risk stratification tool for fall-related injury in a state-wide cohort. BMJ Open, 2017, 7, e012189.	0.8	9
114	Frequency of non-right-handedness in bipolar disorder and schizophrenia. Psychiatry Research, 2017, 253, 267-269.	1.7	18
115	Validation of Polygenic Scores for QT Interval in Clinical Populations. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	17
116	Predicting Suicidal Behavior From Longitudinal Electronic Health Records. American Journal of Psychiatry, 2017, 174, 154-162.	4.0	251
117	Efficient Genome-wide Association in Biobanks Using Topic Modeling Identifies Multiple Novel Disease Loci. Molecular Medicine, 2017, 23, 285-294.	1.9	19
118	Association of Antenatal Depression Symptoms and Antidepressant Treatment With Preterm Birth. Obstetrics and Gynecology, 2016, 127, 926-933.	1.2	39
119	Abandoning personalization to get to precision in the pharmacotherapy of depression. World Psychiatry, 2016, 15, 228-235.	4.8	61
120	Identification of 15 genetic loci associated with risk of major depression in individuals of European descent. Nature Genetics, 2016, 48, 1031-1036.	9.4	655
121	Variation in the oxytocin receptor gene (*OXTR*) is associated with differences in moral judgment. Social Cognitive and Affective Neuroscience, 2016, 11, nsw103.	1.5	30
122	Improving Prediction of Suicide and Accidental Death After Discharge From General Hospitals With Natural Language Processing. JAMA Psychiatry, 2016, 73, 1064.	6.0	106
123	Underreporting of Delirium in Statewide Claims Data: Implications for Clinical Care and Predictive Modeling. Psychosomatics, 2016, 57, 480-488.	2.5	47
124	Psychiatric Pharmacogenomics. , 2016, , 727-747.		1
125	A randomized, placebo-controlled proof-of-concept trial of adjunctive topiramate for alcohol use disorders in bipolar disorder. American Journal on Addictions, 2016, 25, 94-98.	1.3	24
126	Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet, The, 2016, 387, 1085-1093.	6.3	306

#	Article	IF	Citations
127	Discriminating Between Bipolar Disorder and Major Depressive Disorder. Psychiatric Clinics of North America, 2016, 39, 1-10.	0.7	44
128	Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models. Molecular and Cellular Neurosciences, 2016, 73, 104-115.	1.0	49
129	Genomic Studies of Treatment Resistance in Major Depressive Disorder. , 2016, , 55-65.		1
130	Genome-wide association study identifies SESTD1 as a novel risk gene for lithium-responsive bipolar disorder. Molecular Psychiatry, 2016, 21, 1290-1297.	4.1	69
131	Stratifying Risk for Renal Insufficiency Among Lithium-Treated Patients: An Electronic Health Record Study. Neuropsychopharmacology, 2016, 41, 1138-1143.	2.8	73
132	Physician Payments from Industry Are Associated with Greater Medicare Part D Prescribing Costs. PLoS ONE, 2016, 11, e0155474.	1.1	100
133	Antidepressant Nonadherence in Routine Clinical Settings Determined From Discarded Blood Samples. Journal of Clinical Psychiatry, 2016, 77, 359-362.	1.1	9
134	Prevalence of Huntington's disease gene CAG trinucleotide repeat alleles in patients with bipolar disorder. Bipolar Disorders, 2015, 17, 403-408.	1.1	6
135	A Systematic Evaluation of the QTc Interval and Antidepressants in Youth. Journal of Developmental and Behavioral Pediatrics, 2015, 36, 434-439.	0.6	14
136	Practical Radiosynthesis and Preclinical Neuroimaging of [11C]isradipine, a Calcium Channel Antagonist. Molecules, 2015, 20, 9550-9559.	1.7	2
137	Monotherapy Antidepressant Treatment is Not Associated With Mania in Bipolar I Disorder. American Journal of Psychiatry, 2015, 172, 586-586.	4.0	0
138	A Tool to Utilize Adverse Effect Profiles to Identify Brain-Active Medications for Repurposing. International Journal of Neuropsychopharmacology, 2015, 18, pyu078-pyu078.	1.0	8
139	Lifetime prevalence of anxiety disorders in people with bipolar disorder: a systematic review and meta-analysis. Lancet Psychiatry,the, 2015, 2, 710-717.	3.7	113
140	A Clinical Perspective on the Relevance of Research Domain Criteria in Electronic Health Records. American Journal of Psychiatry, 2015, 172, 316-320.	4.0	39
141	Validation of Electronic Health Record Phenotyping of Bipolar Disorder Cases and Controls. American Journal of Psychiatry, 2015, 172, 363-372.	4.0	116
142	Getting Past Proof of Concept For New Treatments. American Journal of Psychiatry, 2015, 172, 937-938.	4.0	0
143	Sentiment Measured in Hospital Discharge Notes Is Associated with Readmission and Mortality Risk: An Electronic Health Record Study. PLoS ONE, 2015, 10, e0136341.	1.1	70
144	A Naturalistic Study of the Effectiveness of Pharmacogenetic Testing to Guide Treatment in Psychiatric Patients With Mood and Anxiety Disorders. primary care companion for CNS disorders, The, 2015, 17, .	0.2	19

#	Article	IF	Citations
145	Stratification of risk for hospital admissions for injury related to fall: cohort study. BMJ, The, 2014, 347, g5863-g5863.	3.0	20
146	USE OF LARGE DATA SETS AND THE FUTURE OF PERSONALIZED TREATMENT. Depression and Anxiety, 2014, 31, 916-919.	2.0	3
147	From Bench to Bedlam. American Journal of Psychiatry, 2014, 171, 1233-1235.	4.0	0
148	Bipolar polygenic loading and bipolar spectrum features in major depressive disorder. Bipolar Disorders, 2014, 16, 608-616.	1.1	21
149	An Electronic Health Records Study of Long-Term Weight Gain Following Antidepressant Use. JAMA Psychiatry, 2014, 71, 889.	6.0	118
150	MAJOR DEPRESSIVE DISORDER IN DSM-5: IMPLICATIONS FOR CLINICAL PRACTICE AND RESEARCH OF CHANGES FROM DSM-IV. Depression and Anxiety, 2014, 31, 459-471.	2.0	260
151	Translation: Screening for Novel Therapeutics With Disease-Relevant Cell Types Derived from Human Stem Cell Models. Biological Psychiatry, 2014, 75, 952-960.	0.7	33
152	Pharmacogenomic Testing and Personalized Treatment of Depression. Clinical Chemistry, 2014, 60, 53-59.	1.5	54
153	Pilot investigation of isradipine in the treatment of bipolar depression motivated by genome€wide association. Bipolar Disorders, 2014, 16, 199-203.	1.1	45
154	Autism spectrum disorder severity reflects the average contribution of de novo and familial influences. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15161-15165.	3.3	125
155	Rare Copy Number Variation in Treatment-Resistant Major Depressive Disorder. Biological Psychiatry, 2014, 76, 536-541.	0.7	67
156	Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. American Journal of Managed Care, 2014, 20, e146-56.	0.8	53
157	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. American Journal of Psychiatry, 2013, 170, 1249-1262.	4.0	579
158	A Clinical Risk Stratification Tool for Predicting Treatment Resistance in Major Depressive Disorder. Biological Psychiatry, 2013, 74, 7-14.	0.7	142
159	A mega-analysis of genome-wide association studies for major depressive disorder. Molecular Psychiatry, 2013, 18, 497-511.	4.1	1,002
160	Association Between Therapeutic Alliance, Care Satisfaction, and Pharmacological Adherence in Bipolar Disorder. Journal of Clinical Psychopharmacology, 2013, 33, 343-350.	0.7	37
161	Common Genetic Variation and Antidepressant Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Genome-Wide Pharmacogenetic Studies. American Journal of Psychiatry, 2013, 170, 207-217.	4.0	216
162	QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ, The, 2013, 346, f288-f288.	3.0	252

#	ARTICLE	IF	CITATIONS
163	First Experience With a Wireless System Incorporating Physiologic Assessments and Direct Confirmation of Digital Tablet Ingestions in Ambulatory Patients With Schizophrenia or Bipolar Disorder. Journal of Clinical Psychiatry, 2013, 74, e533-e540.	1.1	74
164	Antidepressant Response in Patients With Major Depression Exposed to NSAIDs: A Pharmacovigilance Study. American Journal of Psychiatry, 2012, 169, 1065-1072.	4.0	70
165	Using electronic medical records to enable large-scale studies in psychiatry: treatment resistant depression as a model. Psychological Medicine, 2012, 42, 41-50.	2.7	164
166	Biomarkers predicting treatment outcome in depression: what is clinically significant?. Pharmacogenomics, 2012, 13, 233-240.	0.6	44
167	Copy Number Variation in Subjects with Major Depressive Disorder Who Attempted Suicide. PLoS ONE, 2012, 7, e46315.	1.1	24
168	Risks for the Transition From Major Depressive Disorder to Bipolar Disorder in the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry, 2012, 73, 829-836.	1.1	51
169	Do Suicidal Thoughts or Behaviors Recur During a Second Antidepressant Treatment Trial?. Journal of Clinical Psychiatry, 2012, 73, 1439-1442.	1.1	8
170	A critical review of pharmacotherapy for major depressive disorder. International Journal of Neuropsychopharmacology, 2011, 14, 1417-1431.	1.0	54
171	Association of catechol-O-methyltransferase variants with duloxetine response in major depressive disorder. Psychiatry Research, 2011, 189, 475-477.	1.7	11
172	Phenotypic effects of a bipolar liability gene among individuals with major depressive disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 303-309.	1.1	38
173	Variation in TREK1 gene linked to depression€resistant phenotype is associated with potentiated neural responses to rewards in humans. Human Brain Mapping, 2010, 31, 210-221.	1.9	35
174	L€type calcium channels and psychiatric disorders: A brief review. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1373-1390.	1.1	110
175	The International Consortium on Lithium Genetics (ConLiGen): An Initiative by the NIMH and IGSLI to Study the Genetic Basis of Response to Lithium Treatment. Neuropsychobiology, 2010, 62, 72-78.	0.9	134
176	Personalized Medicine for Depression: Can We Match Patients With Treatments?. American Journal of Psychiatry, 2010, 167, 1445-1455.	4.0	283
177	Impact of Substance Use Disorders on Recovery From Episodes of Depression in Bipolar Disorder Patients: Prospective Data From the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). American Journal of Psychiatry, 2010, 167, 289-297.	4.0	103
178	Association Between Bipolar Spectrum Features and Treatment Outcomes in Outpatients With Major Depressive Disorder. Archives of General Psychiatry, 2010, 68, 351.	13.8	118
179	Prevalence of Incompletely Penetrant Huntington's Disease Alleles Among Individuals With Major Depressive Disorder. American Journal of Psychiatry, 2010, 167, 574-579.	4.0	45
180	Genome-Wide Association Study of Suicide Attempts in Mood Disorder Patients. American Journal of Psychiatry, 2010, 167, 1499-1507.	4.0	140

#	Article	IF	Citations
181	Transition to Mania During Treatment of Bipolar Depression. Neuropsychopharmacology, 2010, 35, 2545-2552.	2.8	72
182	Failure to Replicate Genetic Associations with Antidepressant Treatment Response in Duloxetine-Treated Patients. Biological Psychiatry, 2010, 67, 1110-1113.	0.7	89
183	Can Single Genes Matter in a Polygenic World?. Biological Psychiatry, 2010, 68, 783-784.	0.7	4
184	The Association of Single Nucleotide Polymorphisms in the Catechol-O-Methyltransferase Gene and Pain Scores in Female Patients With Major Depressive Disorder. Journal of Pain, 2010, 11, 910-915.e9.	0.7	20
185	Genetic Association Study of Treatment Response With Olanzapine/Fluoxetine Combination or Lamotrigine in Bipolar I Depression. Journal of Clinical Psychiatry, 2010, 71, 599-605.	1.1	45
186	Benzodiazepine Use and Risk of Recurrence in Bipolar Disorder. Journal of Clinical Psychiatry, 2010, 71, 194-200.	1.1	35
187	Clinical Features Associated With Poor Pharmacologic Adherence in Bipolar Disorder. Journal of Clinical Psychiatry, 2010, 71, 296-303.	1.1	88
188	A Genomewide Association Study of Response to Lithium for Prevention of Recurrence in Bipolar Disorder. American Journal of Psychiatry, 2009, 166, 718-725.	4.0	145
189	Manic Symptoms During Depressive Episodes in 1,380 Patients With Bipolar Disorder: Findings From the STEP-BD. American Journal of Psychiatry, 2009, 166, 173-181.	4.0	263
190	Pharmacogenetics Studies in STAR*D: Strengths, Limitations, and Results. Psychiatric Services, 2009, 60, 1446-1457.	1.1	69
191	Genetic and Clinical Predictors of Sexual Dysfunction in Citalopram-Treated Depressed Patients. Neuropsychopharmacology, 2009, 34, 1819-1828.	2.8	88
192	When is Pharmacogenetic Testing for Antidepressant Response Ready for the Clinic? A Cost-effectiveness Analysis Based on Data from the STAR*D Study. Neuropsychopharmacology, 2009, 34, 2227-2236.	2.8	81
193	Irritability is associated with anxiety and greater severity, but not bipolar spectrum features, in major depressive disorder. Acta Psychiatrica Scandinavica, 2009, 119, 282-289.	2.2	81
194	Retrospective age at onset of bipolar disorder and outcome during two‐year follow‐up: results from the STEP‐BD study. Bipolar Disorders, 2009, 11, 391-400.	1.1	229
195	Stability of symptoms across major depressive episodes in bipolar disorder. Bipolar Disorders, 2009, 11, 867-875.	1.1	17
196	Variation in Catechol-O-Methyltransferase Is Associated with Duloxetine Response in a Clinical Trial for Major Depressive Disorder. Biological Psychiatry, 2009, 65, 785-791.	0.7	74
197	Does Study Design Explain the Relationship Between Conflict of Interest and Positive Outcome in Clinical Trials in Psychiatry?. Journal of Clinical Psychopharmacology, 2009, 29, 609-611.	0.7	1
198	Pharmacogenetics Studies in STAR*D: Strengths, Limitations, and Results. Psychiatric Services, 2009, 60, 1446-57.	1.1	50

#	Article	IF	Citations
199	Rating Scales for Bipolar Disorder. , 2009, , 73-86.		0
200	Efficacy of Agents in Treating Mania. Journal of Clinical Psychiatry, 2009, 70, e08.	1.1	0
201	Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nature Genetics, 2008, 40, 1056-1058.	9.4	1,102
202	Euthymic Patients with Bipolar Disorder Show Decreased Reward Learning in a Probabilistic Reward Task. Biological Psychiatry, 2008, 64, 162-168.	0.7	157
203	Pharmacogenetic Analysis of Genes Implicated in Rodent Models of Antidepressant Response: Association of TREK1 and Treatment Resistance in the STAR*D Study. Neuropsychopharmacology, 2008, 33, 2810-2819.	2.8	92
204	Association of a Polymorphism Near CREB1 With Differential Aversion Processing in the Insula of Healthy Participants. Archives of General Psychiatry, 2008, 65, 882.	13.8	45
205	Family-Based Association Study of Lithium-Related and Other Candidate Genes in Bipolar Disorder. Archives of General Psychiatry, 2008, 65, 53.	13.8	55
206	Lithium and Its Role in Psychiatry. , 2008, , 651-659.		0
207	Clinical decision making in the treatment of mania. Journal of Clinical Psychiatry, 2008, 69 Suppl 5, 16-21.	1.1	0
208	Adjunctive Antidepressant Use and Symptomatic Recovery Among Bipolar Depressed Patients With Concomitant Manic Symptoms: Findings From the STEP-BD. American Journal of Psychiatry, 2007, 164, 1348-1355.	4.0	185
209	Association Between Treatment-Emergent Suicidal Ideation With Citalopram and Polymorphisms Near Cyclic Adenosine Monophosphate Response Element Binding Protein in the STAR*D Study. Archives of General Psychiatry, 2007, 64, 689.	13.8	128
210	Cytochrome P450 genotyping and antidepressants. BMJ: British Medical Journal, 2007, 334, 759-759.	2.4	13
211	Treatment-Associated Suicidal Ideation and Adverse Effects in an Open, Multicenter Trial of Fluoxetine for Major Depressive Episodes. Psychotherapy and Psychosomatics, 2007, 76, 40-46.	4.0	65
212	Use of treatment guidelines in clinical decision making in bipolar disorder: a pilot survey of clinicians. Current Medical Research and Opinion, 2007, 23, 467-475.	0.9	37
213	Pharmacogenetic Studies of Antidepressant Response: How Far from the Clinic?. Psychiatric Clinics of North America, 2007, 30, 125-138.	0.7	24
214	Clinical and Genetic Dissection of Anger Expression and CREB1 Polymorphisms in Major Depressive Disorder. Biological Psychiatry, 2007, 62, 536-540.	0.7	38
215	Concordance with treatment guidelines for bipolar disorder: data from the systematic treatment enhancement program for bipolar disorder. Psychopharmacology Bulletin, 2007, 40, 72-84.	0.0	34
216	Predictors of Recurrence in Bipolar Disorder: Primary Outcomes From the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). American Journal of Psychiatry, 2006, 163, 217-224.	4.0	563

#	ARTICLE	IF	CITATIONS
217	Clinical Features of Bipolar Depression Versus Major Depressive Disorder in Large Multicenter Trials. American Journal of Psychiatry, 2006, 163, 225-231.	4.0	189
218	Pharmacogenetics, Race, and Psychiatry: Prospects and Challenges. Harvard Review of Psychiatry, 2006, 14, 92-108.	0.9	26
219	Atypical Antipsychotics in the Treatment of Mania. Journal of Clinical Psychiatry, 2006, 67, 509-516.	1.1	181
220	Olanzapine Versus Risperidone in the Treatment of Manic or Mixed States in Bipolar I Disorder. Journal of Clinical Psychiatry, 2006, 67, 1747-1753.	1.1	81
221	The integration of measurement and management for the treatment of bipolar disorder: a STEP-BD model of collaborative care in psychiatry. Journal of Clinical Psychiatry, 2006, 67 Suppl 11, 3-7.	1.1	6
222	Pharmacogenetic Testing in the Clinical Management of Schizophrenia. Journal of Clinical Psychopharmacology, 2005, 25, 427-434.	0.7	49
223	Industry Sponsorship and Financial Conflict of Interest in the Reporting of Clinical Trials in Psychiatry. American Journal of Psychiatry, 2005, 162, 1957-1960.	4.0	288
224	Revisiting Depressive-Prone Bipolar Disorder: Polarity of Initial Mood Episode and Disease Course Among Bipolar I Systematic Treatment Enhancement Program for Bipolar Disorder Participants. Biological Psychiatry, 2005, 58, 549-553.	0.7	82
225	Prevalence and Clinical Correlates of Irritability in Major Depressive Disorder. Journal of Clinical Psychiatry, 2005, 66, 159-166.	1.1	65
226	The Texas Implementation of Medication Algorithms Update for Treatment of Bipolar I Disorder. Journal of Clinical Psychiatry, 2005, 66, 818-820.	1.1	9
227	Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. Journal of Clinical Psychiatry, 2005, 66, 159-66; quiz 147, 273-4.	1.1	22
228	The role of pharmacologic treatment guidelines for bipolar disorder. Journal of Clinical Psychiatry, 2005, 66 Suppl 3, 37-47.	1.1	1
229	Misdiagnosis of bipolar disorder. American Journal of Managed Care, 2005, 11, S271-4.	0.8	48
230	The prevalence and clinical correlates of anger attacks during depressive episodes in bipolar disorder. Journal of Affective Disorders, 2004, 79, 291-295.	2.0	82
231	Long-Term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biological Psychiatry, 2004, 55, 875-881.	0.7	746
232	Effect of Medical Comorbidity on Response to Fluoxetine Augmentation or Dose Increase in Outpatients With Treatment-Resistant Depression. Psychosomatics, 2004, 45, 224-229.	2.5	25
233	Presence of Irritability During Depressive Episodes in Bipolar Disorder. CNS Spectrums, 2004, 9, 227-231.	0.7	33
234	Evidence-based strategies for achieving treatment goals in bipolar disorder: A review and synthesis of contemporary treatment guidelines. Current Psychosis & Therapeutics Reports, 2003, 1, 85-92.	0.1	2

#	Article	IF	Citations
235	Clinical and sociodemographic predictors of response to augmentation, or dose increase among depressed outpatients resistant to fluoxetine 20â€ƒmg/day. Acta Psychiatrica Scandinavica, 2003, 108, 432-438.	2.2	22
236	Biological predictors of treatment response in affective illness. Psychiatric Clinics of North America, 2003, 26, 323-344.	0.7	8
237	Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biological Psychiatry, 2003, 54, 879-883.	0.7	163
238	Effects of Adding Cognitive Therapy to Fluoxetine Dose Increase on Risk of Relapse and Residual Depressive Symptoms in Continuation Treatment of Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2002, 22, 474-480.	0.7	63
239	Effect of Abrupt Change From Standard to Low Serum Levels of Lithium: A Reanalysis of Double-Blind Lithium Maintenance Data. American Journal of Psychiatry, 2002, 159, 1155-1159.	4.0	75
240	Strategies for treatment of SSRI-associated sexual dysfunction: a survey of an academic psychopharmacology practice. Harvard Review of Psychiatry, 2002, 10, 109-14.	0.9	2
241	Evidence-based pharmacotherapy of major depressive disorder. , 0, , 53-72.		0